Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Goldman Sachs

JPMorgan Chase & Co

Procter & Gamble

Here we discuss four momentum-focused top-ranked Dow Jones stocks -- JPM, GS, PG and MRK -- that are well poised to flourish in 2021 on strong fundamentals.

Dow Jones Jumps 600 Points: Bet on 4 Momentum Stocks to Win Big

eBay

They're not only cheap but they also pay dividends!

2 Value Stocks to Buy With Your $600 Stimulus Check That Can Make You Rich

Amgen

Cisco Systems

Chevron

Dow Inc

Coca-Cola

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Walgreens

The Dogs of the Dow were flea-bitten last year, but this simple dividend-investing strategy will try to return to greatness in 2021.

Dogs of the Dow 2021: 10 Dividend Stocks to Watch

Merck stock slumped 11% last year, lagging both the pharma sector and broader market. Citi analyst Andrew Baum rates shares at Buy and sees them rising 31%.

Merck Stock Is Deeply Undervalued, Says Citi. It Could Surge in 2021.

AbbVie

These two pharmaceutical stocks can significantly boost your wealth in the long run.

Got $1,000? These 2 Top Stocks Can Make You Rich

Boeing

Salesforce

Pfizer

Exxon Mobil

Here are the newest stocks to join the portfolio for those using this easy-to-follow strategy.

Meet the 2021 Dogs of the Dow

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at J.P. Morgan Healthcare Conference

Merck to Present at the 39th Annual J.P. Morgan Healthcare Conference

Strong SACCOVID clinical trial results suggest an approval is forthcoming. Graft versus Host Disease linkage to the most promising therapeutics.

Merck's Recent Acquisition Highlights OWS Funding Flowing Into COVID-19 Therapeutics

SPDR Dow Jones Industrial Average ETF

In the 10 days since we posted our preliminary list of 2021's Dogs of the Dow, more than 23,000 Americans have died from causes related to the COVID-19 pandemic.

2021's Dogs of the Dow

Biogen

Bank of New York Mellon

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Intel

Lockheed Martin

Altria

Roche Holding AG

Sanofi

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The January 2021 Heat Map

Cara Therapeutics

Canopy Growth

GrowGeneration Corp

These 6 cannabis stocks show promise in the medical and recreational ends of the burgeoning marijuana sector, set to grow even more in 2021. The post 6 Cannabis Stocks to Buy as the U.S. Softens Its Stance appeared first on InvestorPlace.

6 Cannabis Stocks to Buy as the U.S. Softens Its Stance

Apple

BancorpSouth Bank

Cadence Bank

CIT Group

Huntington Bancshares

Newmont Mining

Prosperity Bancshares

PNC Financial Services

Regions Financial

Extended Stay America

TCF Financial

Wyndham Hotels & Resorts Inc

Barron's published 36 unique stock mentions and recommendations for 2021 into recent weekly issues. Barron's staff writers Andrew Bary and Lawrence C Strauss contributed. The 36 Barron's Blessed stocks for 2021 included 19 with dividends representing nine of eleven Morningstar Sectors (no Utilities/Energy). Broker targeted-top-ten net gainers ranged 6.48-29.05% 12/28/21.

Meet 19 Barron's Blessed Dividend Dogs For 2021

With just three more trading days left in 2020, there are six stocks on the Dow Jones industrial average index that are trading at least 10% below their closing price at the end of 2019.

The 6 Worst-Performing Dow Stocks of 2020

Big Lots

Alphabet

Block

Walmart

It's still unclear if most companies will emerge from the pandemic unscathed, but for some, there's little doubt they'll be just fine.

As the Sun Sets on 2020, These 5 Stocks Are My Highest-Conviction Holdings

AstraZeneca

The innovative treatment can now be used to help treat prostate, ovarian, and pancreatic cancer in the Asian country.

Merck and AstraZeneca's Cancer Drug Wins 3 New Approvals in Japan

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA® (olaparib) Receives Three New Approvals in Japan

LYNPARZA® (olaparib) Receives Three New Approvals in Japan

MRK entered into a $356 million supply agreement to provide doses of its experimental COVID-19 drug to the government. MRK acquired the COVID-19 treatment (renamed MK-7110) after buying OncoImmune last month.

Merck's COVID-19 Treatment Could Threaten Gilead

Merck (MRK) inks an agreement with the Government of United States for supplying MK-7110, being developed for treating patients with serious COVID-19, if approved.

Merck (MRK) to Supply Coronavirus Treatment to U.S. Government

Atmos Energy

Bristol-Myers

General Dynamics

Pinnacle West Capital

In my monthly series of 10 Dividend Growth Stocks, I rank a selection of dividend growth stocks in Dividend Radar and present the 10 top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to get quality scores and sort them in descending order, breaking ties with additional metrics.

10 Dividend Growth Stocks For December 2020

Johnson & Johnson

Investors have still not fully discounted the negative effect higher corporate tax rates and U.S. price controls on drug prices will have on Merck in 2021-22. Johnson & Johnson's diversification away from traditional pharmaceuticals is very desirable going into 2021.

Johnson & Johnson Vs. Merck: 2021 Long/Short Trade

Merck has reached a multimillion-dollar deal to supply the feds with a coronavirus drug it's developing to treat severely ill patients, the company said Wednesday. The government will pay the New Jersey-based drugmaker up to about $356 million for roughly 60,000 to 100,000 doses of the drug known as MK-7110, according to a news release.

Merck to supply feds with COVID-19 drug under $356M deal

News for Merck Stock (MRK)